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Edited by Michael R. BubbAbstract Angiopoietins and Tie2 receptor were recently identi-
ﬁed as an endothelial cell-speciﬁc ligand-receptor system that is
critical for vascular development and postnatal pathologic angi-
ogenesis by mediating vascular integrity. In this study, we iden-
tiﬁed a series of small-molecule Tie2 inhibitors, which blocked
Ang1-induced Tie2 autophosphorylation and downstream signal-
ing with an IC50 value at 0.3 lM. Further optimization yields
improved selectivity, aqueous solubility, microsomal stability
and cytochrome P450 proﬁle for one of the compounds (com-
pound 7). Both compound 1 and compound 7 inhibit endothelial
cell tube formation. Furthermore, in a rat model of Matrigel-in-
duced choroidal neovascularization, compound 7 signiﬁcantly
diminished aberrant vessel growth. Our ﬁndings demonstrate a
potential clinical beneﬁt by speciﬁcally targeting Tie2-mediated
angiogenic disorders.
 2008 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Abnormal growth of new blood vessels is involved in
promoting diﬀerent ocular pathogenesis including diabetic ret-
inopathy and age-related macular degeneration, the two most
frequent causes of severe and progressive vision loss [1]. Tie2
and angiopoietins are upregulated in the retina from patients
with ischemic retinal disorders [2]. Recent studies demon-
strated that Tie2 plays a key role in mediating both retinopa-
thy and choroidal neovascularization. Immunohistochemistry
with a monoclonal antibody to human Tie2 showed a promi-
nent expression of Tie2 around and within the base of newly
formed blood vessels of retinal and choroidal neovascular le-
sions. Soluble Tie2 receptor inhibits experimental retinal and
choroidal neovascularization [1,2]. Systemic soluble Tie2
expression also inhibits and regresses corneal neovasculariza-
tion [3].
Two families of receptor tyrosine kinases, VEGFR1/VEG-
FR2 and Tie2, have been shown to be critical factors in con-*Corresponding author. Fax: +1 609 655 4187.
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with their respective ligands, VEGFs and angiopoietins
(Ang1 and Ang2) [4]. Interestingly, accumulating evidence
suggests that Tie2 activation, through collaboration with
VEGFR, regulates the pathological angiogenesis in a synergis-
tic fashion [5], and combination of soluble Tie2 and VEGFR
additively suppresses retinal angiogenesis [2]. These results
indicate that the Tie2 signaling network, along with VEGF/
VEGFR, is an important cascade in the induction and progres-
sion of the aberrant angiogenesis in ocular disorders. Inhibi-
tion of Tie2 signaling may provide a potentially viable
therapeutic strategy in the treatment of ocular diseases due
to the abnormal neovascularization.
In this study, approximately four million compounds, gener-
ated through Encoded Combinatorial Libraries on Solid Sup-
port (ECLIPS) technology [6], were screened in an attempt to
identify selective small-molecule Tie2 kinase inhibitors.
Through the screening and subsequent medicinal chemistry
eﬀorts, a selective small-molecule Tie2 inhibitor was identiﬁed
(compound 7). A rat choroidal neovascularization model was
used to investigate the in vivo eﬃcacy of the compound. Our
results clearly demonstrated that the Tie2 inhibitor markedly
block the aberrant blood vessel formation in this animal
model.2. Materials and methods
2.1. Cell culture
Human aortic endothelial cells (HAECs) were maintained in endo-
thelial basal media (EBM) (BioWhittaker, Baltimore, MD) supple-
mented with 10% fetal bovine serum and the EGM kit containing
growth factors (BioWhittaker). HAECs were used in cell-based assays
between passage 6 and passage 8.
2.2. High throughput screen for Tie2 kinase inhibitors using a
homogeneous time-resolved ﬂuorescence (HTRF) assay
The assay was performed in 384-well black Costar plates. Substrate
mix containing ﬁnal concentrations of 1.5 lg per ml of biotinyl poly-
Glu, Ala, Tyr and 1 lM ATP in assay buﬀer (50 mM HEPES, pH
7.4, 0.2 mM Na3VO4, 1 mM DTT, 25 mM MgCl2, 5 mM MnCl2,
0.01% BSA and protease inhibitor cocktail) was added to each well fol-
lowed by adding Tie2 enzyme to initiate the reaction. After incubation
for 75 min at room temperature, the reaction was terminated by add-
ing stop/detection solution containing streptavidin-APC and Euro-
pium-anti-phospho-tyrosine antibody. The plates were read by a
cooled CCD imager (ViewLux, Perkin Elmer, Boston, MA) at both
615 nm and 665 nm. The screening data were analyzed using the ratio
of the 665 nm to 615 nm ﬂuorescence signal.blished by Elsevier B.V. All rights reserved.
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Ang1 was purchased from R&D Systems. Before use, Ang1 was pre-
incubated with anti-poly-histidine antibody (R&D Systems, Minneap-
olis, MN) to form dimers prior to the treatment of HAECs. Equal
numbers of HAECs were grown to conﬂuent monolayer and starved
with serum-free EBM medium for 6 h. HAECs were pretreated with
Tie2 inhibitors or the carrier DMSO (ﬁnal concentration at 0.5%)
for 1 h followed by the stimulation with dimerized Ang1 for 10 min
at 37 C. The same amount of protein was loaded into each well of
SDS–PAGE.2.4. Microsomal stability analysis
The compound stability in human liver microsome was evaluated as
described previously [7].
2.5. CYP450 inhibition assay
Major isoforms of recombinant CYP450 (3A4, 1A2, 2C9, 2C19, and
2D6) and assay kits were obtained from the Gentest (BD biosciences,
Bedford, MA). Eight diﬀerent compound concentrations were used for
the evaluation of inhibitory eﬀect of the compounds on CYPs. The
IC50 values against each CYP450 isoform were determined in duplicate
for the test compounds by monitoring the production of ﬂuorescent
metabolite as described by the manufacturer.2.6. Solubility study
Aqueous solubility analysis was performed by Absorption Systems
(Exton, PA). Brieﬂy, the test article was accurately weighed and sus-
pended in pH 7.4 phosphate buﬀer. The sample was agitated for
approximately 2 h and allowed to stand overnight followed by ﬁltra-
tion through a 0.45 lm nylon syringe ﬁlter. Dilutions of the test com-
pounds were made in 80% buﬀer/20% acetonitrile from a 10 mM stock
solution in DMSO to achieve 1, 0.3, 0.1, 0.03, and 0.01 lM ﬁnal con-
centrations. The standards and ﬁltrates were assayed by LC/MS using
a generic gradient method.
2.7. Endothelial cell tube formations
The tube formation assay was conducted as described [12]. HUVECs
at 30000 cells/well, were cultured on 300 ll growth factor reduced
Matrigel (BD biosciences) in M199 and 0.5% fetal calf serum. The con-
trol wells included either no Ang1 or 100 ng/ml Ang-1, and the treated
well contains both Ang-1 and 5 lM of the test compound. The cells
were incubated for 18 h at 37 C, 5% CO2 and were ﬁxed with 2.5%
glutaraldehyde followed by staining with 0.02% toludine blue. The
gel was dried prior to imaging. The tube length was quantiﬁed using
the NIH image J software. Results are represented as total tube length
(mm) for three photographic ﬁelds per experimental condition. Each
treatment was performed in duplicate and the experiments were re-
peated three times.
2.8. Rat model of choroidal neovascularization (CNV)
Sprague–Dawley rats (female, 2 months old) were purchased from
Harlan Laboratories (Indianapolis, IN). Subretinal injections of
Matrigel (growth factor reduced, BD Biosciences) were performed
on the temporal side of the eye under a microscope. Rats were anesthe-
tized by intraperitoneal injection of ketamine (40 mg/kg) and xylazine
(6 mg/kg). The sclera was exposed and an incision was made between
the limbus and the equator with a sharp #33 needle to reach the sub-
retinal space. The tip of a blunt #33 needle attaching to a Hamilton
micro-syringe was introduced to the incision at a shallow angle toward
the posterior pole and inserted 0.1–0.2 mm into the subretinal space for
injection. Matrigel was diluted with phosphate buﬀered saline (vehicle)
or compound 7 (ﬁnal concentration: 10 lg/ll) in the vehicle at 3:1 (75%
gel). Gel solution (1.2 ll) was slowly injected so the solution pushed its
way into the subretinal space. Injected solution normally solidiﬁed
within minutes and formed a bleb of 1.5–2 mm in diameter with the
injection site at the anterior edge.
Blood vessels were directly labeled with a solution containing a ﬂuo-
rescent carbocyanine dye DiI (1,1 0-dioctadecyl-3,3,3 0,3 0-tetramethylin-
docarbocyanine perchlorate, Sigma–Aldrich, St. Louis, MO). Animals
were sacriﬁced by CO2 overdose and perfused with PBS, followed by a
solution containing DiI. The animal was subsequently perfused with
4% paraformaldehyde (in 0.1 M phosphate buﬀer, pH 7.4). Eyes were
harvested and the anterior segments removed. The eyecups were post-ﬁxed in the same ﬁxative overnight and then transferred to PBS at
4 C. For each eye, serial sections were obtained for the entire Matrigel
injected area. Typically, 20–24 sections (100 lm of each) of each eye
were used for analysis. Tissue was embedded in 5% agarose. Thick
(100 lm) serial sections were cut on a vibratome (VT1000S, Leica
Microsystems, Bannockburn, IL), mounted on glass slides with 80%
glycerol, and examined by confocal microscopy. CNV index of an
eye was calculated according to the following equation:
C ¼ TPni¼1Wi, where C is the CNV index, T is the thickness of a sec-
tion, W is the measured width of CNV in a particular section, and i
is the series number of the section. Each section has its own CNV in-
dex, which varies from section to section in the same eye. The index for
the whole eye is the sum of all serial sections. Statistical analysis was
performed and data are presented as mean ± S.D. Students t-test
was used to evaluate the diﬀerence of CNV indexes between the control
and each treated group.3. Results and discussion
3.1. Discovery and characterization of small-molecule inhibitors
of Tie2
We established a Tie2 kinase assay using recombinant GST
Tie2 kinase domain fusion protein as the source of the enzyme.
Enzyme kinetic studies of the recombinant Tie2 kinase domain
revealed that the apparent Km for ATP was 60 lM (data not
shown). To conduct high throughput screening of approxi-
mately four million compounds divided among 89 combinato-
rial libraries, a HTRF assay was established using biotinyl
poly-Glu, Ala, Tyr as the substrate. The ATP concentration
was adjusted to 1 lM in the screen. Tie2 inhibitors were iden-
tiﬁed from one speciﬁc library based on a glycinyl carbamate,
and incorporating a key biaryl substituent. Several analogs
were generated in this active series with examples shown in Ta-
ble 1 and supplementary Fig. 1. Compounds incorporating a
butyl carbamate (compound 1) and benzyl carbamate (com-
pound 2) produced concentration-dependent inhibition of
Tie2 kinase activity with IC50 values of 3.2 lM and 2.1 lM,
respectively. In all active compounds, the biaryl moiety was
present as a para-(pyridin-3-yl)benzyl (compounds 1, 2 and
7) or a para-(pyrimidin-5-yl)benzyl substituent (compound 5)
of the glycinyl nitrogen, providing a hydrogen bond acceptor
at the 3-position of the terminal aromatic ring. The importance
of the 3-position hydrogen-bond acceptor within the biaryl
component (R3) is demonstrated since the phenyl substituted
(compound 3) and the 4-pyridyl (compound 4) analogs showed
only weak activity (Fig. 1A and Table 1).
Compound 2 was selected from the series to investigate the
inhibitory mechanism of Tie2 kinase activity. Kinetic experi-
ments were performed by varying the ATP levels at several
inhibitor concentrations. The results suggest that compounds
within this series competitively interact with the Tie2 kinase
domain at the ATP binding site (Supplementary Fig. 2).3.2. Speciﬁc blockade of Ang1-triggered Tie2-mediated signaling
cascade
Studies have demonstrated that activation of the Tie2 recep-
tor by Ang1 leads to auto-phosphorylation of Tie2 [8,9]. Since
Tie2 is predominantly expressed and functions on endothelial
cells, HAECs, which express high levels of the Tie2 receptor,
were chosen to evaluate the cellular functions of the Tie2 inhib-
itors. We assessed the eﬀect of compound 1 on Tie2 auto-phos-
phorylation. It was demonstrated that compound 1 blocked
Tie2 auto-phosphorylation in a concentration-dependent
Table 1
Blocking in vitro Tie2 kinase activity by small-molecule Tie2 inhibitors
Compound R1 R2 R3 Ki binding (lM)
1
O
N
3.2 ± 0.7
2 O
N
2.1 ± 0.4
3 O >100
4 O
N
>80
5 O
N
N
1.2 ± 0.1
6 O
N
N
>100
7
O
N
OH
O
1.3 ± 0.2
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imately 0.3 lM in this cellular assay. Compound 3, an analog of
compound 1, which does not inhibit Tie2 activity in the kinase
assay (IC50 > 100 lM), showed little inhibitory eﬀect in the
same cell-based assay (Fig. 1C). Stimulation of Tie2 receptor
by Ang1 further leads to the activation of its downstream sig-
naling pathway through p42/p44 Erk and Akt [8,9]. Ang1
was previously shown to activate the MAPK signaling cascade
in human umbilical vein endothelial cells (HUVECs). The
pharmacological inhibition of Erk activation with the MEK
inhibitor, PD98059, suppressed Ang1-induced migration [10].
A short synthetic peptide, identiﬁed as a speciﬁc blocker of
Tie2 and Ang1/Ang2 interaction, was shown to abolish the
phosphorylation of p42/p44 Erk induced by Ang1 [8]. There-
fore, the compound eﬀect on these downstream cellular events
was also investigated. Consistent with the previous ﬁndings, we
observed a strong activation of p42/p44 Erk and Akt after
Ang1 induction, and these activities were attenuated by the
small-molecule Tie2 inhibitors. As shown in Fig. 1C, at
10 lM compound concentrations, compound 1 completely
abolished the activation of p42/p44 ERK and Akt induced by
Ang1, whereas the inactive analog, compound 3, displayed little
activity on the cellular Tie2 signal transduction pathways. Two
additional analogs were also investigated for their ability to
block Ang1/Tie2 signaling in HAECs. Compound 5 and com-
pound 6 correspond to the S- andR-enantiomers of the a-meth-
ylated cyclohexylmethyl amides, respectively. Inhibition of
Tie2 kinase activity was demonstrated with the S-isomer (com-
pound 5) at an IC50 value of 1.2 lM versus the inactive R-iso-
mer (compound 6) with an IC5 over 100 lM (Table 1). In
agreement with the kinase activities, compound 5 completely
blocked Ang1-induced Tie2 receptor autophosphorylation
along with activation of p42/p44 Erk and Akt when screened
at 1 and 3 lM (Fig. 1D). The Tie2 inactive analog, compound
6, did not block the Ang1 induction of Tie2 receptor phosphor-
ylation. Thus, compounds within this series show a requirement
for 3-position nitrogen at R3 and a speciﬁc chirality at R1 fortheir inhibitory eﬀects, which are reﬂected both at the kinase
and cell-based functional levels of the Tie2 receptor.
To further investigate that the inhibitory eﬀects of com-
pound 1 were speciﬁcally through the Tie2-associated path-
way, cellular assays were performed to monitor the
activation of two other receptor tyrosine kinases, EGFR and
c-Met, induced by their cognate ligands, EGF and HGF,
respectively, using the same cellular system as Tie2. Similar
to the stimulation by Ang1, both EGF and HGF were capable
of inducing their receptor autophosphorylation and the phos-
phorylation of p42/p44 Erk and Akt. However, although com-
pound 1 at 10 lM showed strong inhibition on Ang1-induced
Tie2 receptor, p42/p44 Erk and Akt phosphorylation, no
inhibitory eﬀects were observed on EGFR or c-Met receptor
phosphorylation and downstream ERK and Akt activation.
As a control, PD98059, a MAP kinase kinase (MEK) inhibi-
tor, was included in these studies and, as anticipated, the com-
pound displayed a signiﬁcant inhibition on p42/p44 ERK
phosphorylation triggered by all three receptors including
Tie2, EGFR and c-Met with little eﬀect on Akt activation
(Fig. 2A–C). These results indicated that the observed eﬀect
of compound 1 was most likely through speciﬁc inhibition of
Ang-1-triggered Tie2 activation pathway and not through its
eﬀect on other kinases or cytotoxicity. Consistently, no cyto-
toxicity was observed for compound 1 at concentration up to
50 lM using PC3 and THP1 cells (data not shown). However,
subsequent studies in a kinase selectivity panel indicated that
compound 1 blocked JNK1 and VEGFR2 with IC50 values
of 3.9 lM and 6.6 lM, respectively. To selectively target Tie2
signaling pathway, further improved kinase selectivity was de-
sired. Compound 7 was identiﬁed and possessed an IC50 value
of 1 lM against the Tie2 receptor in the kinase assay (Table 1).
Further cell-based studies also indicated that the compound
inhibited Ang1-induced Tie2 autophosphorylation and p42/
p44 ERK phosphorylation with IC50value of approximately
0.3 lM (data not shown and Fig. 1E). No cytotoxicity was ob-
served for compound 7 up to 50 lM using PC3 and THP1
Fig. 1. Inhibitory eﬀect on Tie2 auto-phosphorylation and its downstream signaling events in response to Ang1 stimulation. (A) Dose dependent
inhibition of in vitro Tie2 kinase activity. Various concentrations of compound 1 or compound 3 were included in the Tie2 kinase assay in the
presence of 1 lM ATP. (B) Inhibition of Ang1-induced Tie2 auto-phosphorylation by compound 1. Various concentrations of the compound were
incubated with HAECs for 15 min followed by incubating with Ang1 for an additional 15 min. Tie2 was immunoprecipitated, and its
phosphorylation was detected by immunoblot using an anti-phospho-tyrosine antibody. The arrowhead denotes phosphorylated Tie2. The estimated
IC50 value was approximately 0.3 lM in this cellular assay. (C) Eﬀect of Tie2 inhibitors on the activation of Tie2, p42/p44 Erk and Akt by Ang1 in
HAECs. HAECs were stimulated with 200 ng/ml Ang1 for 15 min. Phosphorylation of Tie2 and its downstream signaling proteins, p42/p44 Erk and
Akt, were detected by immunoblot using ant-phosph-p42/p44 Erk and anti-phospho-Akt antibodies, respectively. The eﬀect of compound 1 or
compound 3 on Ang1-induced activation pathways were evaluated by incubating HAECs with an active Tie2 inhibitor (compound 1) or an inactive
Tie2 compound (compound 3) at 10 lM concentration for 15 min, prior to the stimulation by Ang1 for an additional 15 min. (D) Inhibition of Ang1-
induced phosphorylation of Tie2, Akt and p42/p44 Erk. HAECs were investigated in the presence of compound 5 or compound 6, a pair of
enantiomers, at 1 and 3 lM for 15 min, followed by stimulating with Ang1 for an additional 15 min. Equal amount of total cell lysates or
immunoprecipitated proteins were separated by SDS–PAGE under reducing conditions. Phosphorylation of Tie2, p42/p44 Erk and Akt was
measured by immunoblotting. (E) HAECs were treated with various concentrations of compound 7 for 15 min, prior to incubating with Ang1 for an
additional 15 min. Phosphorylation of p42/p44 Erk was analyzed by anti-phospho-p42/p44 Erk immunoblot. The estimated IC50 value is 0.3 lM.
The blot was also detected with anti-b-actin antibody to ensure the equal loading. The experiments were repeated three times.
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17 tested protein kinases up to 20 lM compound concentra-
tions (Supplementary, Table 1).
3.3. Improved physicochemical properties for compound 7
Several other key features of compound 1 were also found to
be suboptimal for in vivo assessment, including poor in vitro
human liver microsome (HLM) stability, a marginal cyto-
chrome P450 inhibition proﬁle and low aqueous solubility
(Table 2). Signiﬁcantly improved HLM stability was achieved
with compound 7, showing over 60% of parent compound
remaining, whereas compound 1 was rapidly metabolized with
0% remaining under the same condition. In contrast to the
strong inhibition on diﬀerent CYP P450 isoforms by com-
pound 1, no signiﬁcant inhibition on a CYP was observedfor compound 7 up to 20 lM compound concentration. Fur-
thermore, compound 7 demonstrated over 150-fold increase
in aqueous solubility compared with compound 1. These
improvements are critical for further evaluating the compound
in vivo eﬃcacy using animal models.
3.4. Reduced tube formation upon treatment with compound 1
and compound 7
Ang1, through interaction with Tie2, has been shown to pro-
mote sprouting, cell survival and migration of endothelial cells
[11–13]. Ang1 was also demonstrated to have direct eﬀect on
endothelial cell behavior during vascular remodeling. In the
presence of Ang1, endothelial cells formed a well-organized net-
work of non-fragmented, cordlike vascular structures on the
Matrigel surface [14]. In this study, the eﬀect of Tie2 inhibitors,
Fig. 2. Selectivity of compound 1 in cellular assays. HAECs were pretreated with compound 1 at 10 lM and PD98059, a MEK inhibitor, at 5 lM, or
the vehicle, 0.5% DMSO, for 15 min. HAECs were then stimulated with Ang1(200 ng/ml), EGF (10 ng/ml), or HGF (20 ng/ml) for an additional
15 min. Phosphorylation of EGF receptor (A), c-Met (B), p42/p44 Erk and Akt (C) was detected by immunoblotting as described under Section 2.
Data are representative of three experiments.
Table 2
Improved CYP proﬁle and solubility of compound 7 versus compound
1
Compound Compound 1 Compound 7
Human liver microsomes
(% of remaining)
0 66
IC50 for CYPs (1A2, 2C9,
2C19, 2D6, 3A4) 3A4 = 1 lM,
2C9 = 5.9 lM
2C19 = 1.6 lM
1A2 > 20 lM
2D6 = 2 lM
> 20 lM
Aqueous solubility 0.4 lM 60 lM
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network formation was investigated using HAECs in Matrigel
system. The presence of Ang1 stimulated the capillary network
formation of endothelial cells on theMatrigel, resulting in more
robust tube-like structures compared with the control without
Ang1. Compound treatment resulted in statistically signiﬁcant
inhibition on the tube formation (Fig. 3A and B). Interestingly,
compound 1 treatment results in more severe disorganized vas-
culature in comparison with the eﬀect of compound 7. This is
likely due to the broader activity of compound 1with IC50 value
around 6 lM against VEGFR2. The source of VEGF likely
came through endogenous secretion from HAECs [15]. Studies
have shown that induction of tube formation by Ang1 is at least
partially dependent on the presence of VEGF [16]. Our current
results appear to support this conclusion. Additional studies areneeded to provide further clariﬁcation. It was found that the
Ang1-promoted tube formation was primarily due to suppres-
sion of apoptosis of endothelial cells in a PI3-kinase-dependent
manner [13]. Interaction of Ang1 and Tie2 leads to the activa-
tion of Akt, which is an important mediator of cell survival
and motility. Studies have shown that Akt is required and suﬃ-
cient to regulate endothelial cell survival in response to growth
factor depletion. Blocking Akt diminished Ang1-mediated
endothelial cell survival, a process that is essential for the tube
formation mediated by Ang1/Tie2 interaction [17]. Further-
more, activating Akt rescues a Tie2 blockade-induced apoptosis
of endothelial cells, and soluble Tie2 receptor has been shown to
promote apoptosis of endothelial cells in culture [16]. Although
stimulation of Tie2 with Ang1 leads to Akt and MAPK/ERK
activation, blocking MAPK/ERK activity with a speciﬁc inhib-
itor PD98059 did not aﬀect endothelial cell survival [17], indicat-
ing that Akt is the dominant mediator of Ang1-induced cell
survival. In addition, it was also shown that Akt activity is re-
quired for endothelial cell sprouting in a three-dimentional col-
lagen gel induced by Ang1 [18]. Similar to the eﬀect of Tie2
blockade for the cellular inhibitory eﬀects on the Ang1/Tie2 sig-
nal transduction pathway, administration of Tie2 blockers,
including dominant negative Tie2 receptor or inhibitory pep-
tide, resulted in inhibition of angiogenesis in chick chorio-
allantoic membrane (CAM) assay, retinal/choroidal
neovascularization and tumor growth [1,19–22].Our studydem-
onstrated that compound 1 and compound 7, attenuated the
Ang1-induced Tie2-associated signaling network including acti-
vation of p42/p44 Erk and Akt (Fig. 1C and D) and further
Fig. 3. Inhibition of tube formation by compound 1 and compound 7. HAECs were seeded on Matrigel in the absence or presence of Ang1 only
(control), and in the presence of Ang1 and 5 lM compound 1 or compound 7. The cells were incubated at 37 C and 5% CO2 for 18 h. The
morphological changes of the cells were observed and photographed under microscope. (A) Representative images of the tube formation of HAECs
when treated with compound 1 or compound 7. (B) Quantitative data on the eﬀect of compound 1 or compound 7 on the tube formation of HAECs.
**P < 0.01 compared to control, n = 3.
790 J. Liu et al. / FEBS Letters 582 (2008) 785–791resulted in the blockade of endothelial tube formation mediated
by Tie2. These results are consistent with other studies showingFig. 4. Attenuated Matrigel-induced rat choroidal neovascularization by co
vessels in a normal retina are shown in panel A. A dense network of new bloo
layer 10 days after subretinal injection of Matrigel (panel B). Scale bar: 100 l
10 animals. Animals were killed at 10 days. Each bar represents the mean ± S.
test.a critical role of the angiopoietins/Tie2 receptor pathway in
mediating vascularization [18,19,22].mpound 7. (A) The network of choroidal (C) and retinal (R) blood
d vessels originated from choriocapillaris (CNV) invaded the Matrigel
m. (B) Eﬃcacy of compound VII on the rat CNV. Each group contains
D. from 10 animals. ***P < 0.001 versus PBS-treated group, Students t-
J. Liu et al. / FEBS Letters 582 (2008) 785–791 7913.5. Compound 7 reduces Matrigel-induced choroidal
neovascularization in rats
Tie2 expression is prominent around and within the base of
newly formed blood vessels of retinal and choroidal neovascu-
lar lesions. Soluble Tie2 receptor that prevents binding of
angiopoietins to the Tie2 receptor on the cell surface has dis-
played eﬃcacy in experimental retinal and choroidal neovascu-
larization [1]. In this study, we investigated whether the Tie2
inhibitor, compound 7, is eﬃcacious in a rat model of Matri-
gel-induced choroidal neovascularization. When injected into
the subretinal space, Matrigel formed a layer between the chor-
oids/retinal pigment epithelium and the retina. Many new
blood vessels originating from the choriocapillaris invaded
the Matrigel layer to form a dense network (Fig. 4A). Matrigel
alone (diluted with PBS) was injected into one eye of an animal
as control, and the contralateral eye was injected with Matrigel
containing the Tie2 inhibitor. Animals were sacriﬁced at day
10 after injection and the eyes were collected. Compound 7
markedly attenuated CNV in this animal model and the
CNV index in the compound treated eyes was reduced by
80% (***P < 0.001) (Fig. 4B). The compound showed striking
in vivo eﬃcacy in the rat model of choroidal neovasculariza-
tion, suggesting an essential and independent role of Tie2-med-
iated angiogenesis versus that of VEGFR2 in controlling the
progression of the disease, since compound 7 has no eﬀect
on VEGFR2 activity at the concentration administered. Inter-
estingly, recent observations showed that angiopoietins can
also bind to Tie1, another important kinase in regulating angi-
ogenesis [23]. The activity of compound 7 against Tie1 kinase
remains to be determined. Nevertheless, our data provide fur-
ther evidence that the Tie2 receptor is an important target
responsible for mediating aberrant vascular growth, and
blocking Tie2 activation with selective inhibitors may provide
a new approach for treating pathological neovascularization.
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